CD19-specific CART cells demonstrated unexpected positive results, achieving complete
remission and durable response in relapsed and refractory patients affected by B-lineage
neoplasms. We recently established a platform for non-viral gene manipulation of Cytokine-Induced
Killer (CIK) cells, an effector T cell population characterized by enrichment in highly
cytotoxic CD3+CD56+ cells and reduced risk of GvHD, in compliance with Good manufacturing
practices (GMP).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
